What FDA found
FDA has received reports of people administering five to twenty times the intended amount of compounded semaglutide. Some sought medical attention or were hospitalized. The agency describes mistakes by both patients and health professionals, including errors converting a prescribed amount into syringe markings. These are reported cases, not a measured rate among everyone using compounded semaglutide. [1]
For background, see semaglutide prescribing information before applying a general claim to a particular product.
The important lesson is that an instruction can appear precise while still being incomplete. A number of units means little without the concentration and the syringe scale. A refill can look familiar but contain a different concentration. Clear instructions should connect the prescribed medicine, the actual vial and the supplied device before a patient prepares an injection.
Three quantities that should never be treated as synonyms
Milligrams describe an amount of drug. Milliliters describe a volume of liquid. Syringe units are markings on a particular scale. Moving between them requires information about the product concentration and the device. FDA identifies confusion among these quantities as a contributor to overdoses. [1] A saved screenshot from a previous pharmacy cannot establish the right marking for a new prescription.
This article deliberately provides no conversion chart. A chart detached from your current label can reproduce the very problem FDA describes. Ask the pharmacist to explain how the written prescription corresponds to the exact syringe supplied. If the pharmacy changes the preparation or device, request a fresh explanation rather than carrying an old number forward.
A refill needs its own check
Compare the new label with the previous prescription before putting the package away. Look for a changed concentration, added ingredient, different vial size or different syringe. A label stating the same medicine name does not establish that the amount of liquid is unchanged. FDA notes that a single compounder may supply more than one concentration. [1]
If two documents disagree, send both to the pharmacy. Ask which is current and request corrected instructions in writing. Do not choose the instruction that looks most familiar. A conversation that ends with an unresolved discrepancy has not established a safe plan. The pharmacy should connect its answer to your specific fill rather than to a generic website diagram.
What a useful demonstration includes
Ask the pharmacist to identify the prescribed amount, the corresponding volume and the correct marking on the exact syringe. Then explain the instructions back in your own words so a misunderstanding can be caught before use. FDA specifically encourages compounders and clinicians to provide an appropriate syringe size and counsel patients on measuring the intended dose. [1]
Also ask what to do if you cannot read the label or the syringe. Enlarging a photo may help you communicate with the pharmacist, but it does not replace a correct label or suitable device. Keep the final written directions with the vial. Anyone helping with administration should receive the same instructions rather than an abbreviated message relayed from memory.
If you think too much was administered
Get prompt medical advice. Severe symptoms or a suspected emergency require emergency medical care. Do not wait for an email response from a subscription service. Have the vial, prescription details and the time of administration available. FDA describes severe gastrointestinal symptoms and other complications in reports and notes that semaglutide’s long half-life can require prolonged observation and treatment. [1]
Do not try to counteract the error with an extra medicine or decide the next dose yourself. The clinician evaluating the situation needs the actual amount if known, the concentration, other medicines and the symptoms. If the amount is uncertain, say so. An honest estimate is more useful than a falsely exact number reconstructed from a different vial.
Reporting the problem helps the next patient
FDA encourages patients, clinicians and compounders to report medication errors involving compounded semaglutide to MedWatch. [1] Reporting can include a confusing label or product-use error as well as a suspected reaction. Keep the lot number and packaging information when available. Describe the sequence of events and distinguish what the label said from what was actually administered.
A MedWatch report is not emergency treatment, proof of causation or a refund request. It adds information to safety surveillance. [3] Contact the pharmacy about correcting the instructions and the prescriber about the treatment plan separately. The practical aim is to resolve the immediate problem and make the instruction failure visible to the people who can prevent it recurring.
Read the evidence in context
See semaglutide prescribing information for the related details and source material.
See storage and handling of peptides for the related details and source material.
See semaglutide side effects for the related details and source material.